Cas9 nuclease-mediated disruption of the +58-kb erythroid-specific BCL11A enhancer has been recently approved as a clinical therapy for patients with SCD and β-thalassemia.9 The gene discussed is BCL11A; the disease is Schnyder corneal dystrophy.